SELECTED Publications

1. Morris CR, Morris SM, Jr., Hagar W, et al. Arginine Therapy:  A new treatment for pulmonary hypertension in sickle cell disease? Am J Respir Crit Care Med 2003;168:63-69.
2. Lopez B, Kreshak A, Morris CR, et al. L-arginine levels are diminished in adult acute vaso-occlusive sickle cell crisis in the emergency department. Br J Haematol 2003;120:532-534.
3. Morris CR, Kuypers F, Kato G, et al. Hemolysis-associated pulmonary hypertension in thalassemia. An NY Acad Sci 2005:in press.
4. Morris CR, Kuypers FA, Larkin S, et al. Arginine therapy:  A novel strategy to increase nitric oxide production in sickle cell disease. Brit J Haematol 2000;111:498-500.
5. Morris CR, Kuypers FA, Larkin S, et al. Patterns of arginine and nitric oxide in sickle cell disease patients with vaso-occlusive crisis and acute chest syndrome. J Pediatr Hematol Oncol 2000;22:515-520.
6. Morris CR, Vichinsky EP, van Warmerdam J, et al. Hydroxyurea and arginine therapy: impact on nitric oxide production in sickle cell disease. J Pediatr Hematol Oncol 2003;25:629-634.
7. Morris C, Vichinsky E, Styles L. Clinician assessment for acute chest syndrome in febrile patients with sickle cell disease: is it accurate enough? Ann Emerg Med 1999;34(1):64-9.
8. Morris CR. New strategies for the treatment of pulmonary hypertension in sickle cell disease:  The rationale for arginine therapy. Treat Respir Med 2005;in press.
9. Morris CR, Kato GJ, Poljakovic M, et al. Dysregulated arginine metabolism, hemolysis-associated pulmonary hypertension and mortality in sickle cell disease. JAMA 2005;294:81-90.
10. Kato GJ, McGowan V, Machado RF, Little J, Taylor J, Morris CR, Coles W, Hunter L, Nichols, J, Wang X, Poljakovic M, Morris SM Jr, Gladwin MT.  Lactate dehydrogenase as a biomarker of hemolysis-associated nitric oxide resistance, priapism, leg ulceration, pulmonary hypertension and death in patients with sickle cell disease. Blood. 2005 Nov 15; [Epub ahead of print].
11. Morris CR, Kato GJ, Vichinsky EP, et al. Arginine metabolism, pulmonary hypertension, and sickle cell disease. JAMA 2005:294:2432-2434.
12. Morris CR, Poljakovic M, Lavrisha L, et al. Decreased arginine bioavailability and increased serum arginase activity in asthma. Am J Respir Crit Care Med 2004;170:148-153.
13. Hagar W, Morris CR, Vichinsky E.  Pulmonary hypertension in thalassemia major patients with normal left ventricular systolic function.  Brit J Hematol, in press.

1. Morris CR, Kato G, Poljakovic M, Blackwelder WC, Hazen S, Vichinsky EP, Morris SM Jr, Gladwin M.  The arginine-to-ornithine ratio: Biomarker of arginase activity and predictor of mortality in sickle cell disease. Blood  2004, 104:71a-72a [abstract 233] .
2. Morris CR, Gardner J, Hagar W, Vichinski EP.  Pulmonary hypertension in sickle cell disease:  A common complication for both adults and children. . Blood 2004, 104:463a [abstract 1666].
3. Morris CR, Teehankee C, Kato G, et al. Decreased arginine bioavailability contributes to the pathogenesis of pulmonary artery hypertension. In: American College of Cardiology Annual Meeting; 2005 March 6-9; Orlando, Florida; 2005.
4. Morris CR, Gardner J, Wen A, et al. Abnormal pulmonary function in adults and children with sickle cell disease. In: The 28th Annual Meeting of the National Sickle Cell Program; 2005; Cincinnati, Ohio; 2005.
5. Morris CR, Kuypers FA, Lavrisha L, et al. Elevated arginase activity and limited arginine bioavailability:  A common feature of asthma and sickle cell disease. Blood 2003;102:764a (abstr 2819)
6. Schribner C, Blue B, Morris CR. Viral meningitis: When is outpatient management safe? Annual meeting of the Society for Pediatric Research, San Francisco, CA, April 2006
7. Mansour KM, Kuypers FA, Larkin SK, Wang TN, Morris CR.  Serum Phospholipase A2: A biomarker of serious bacterial infection in children presenting with fever to a pediatric emergency department. Annual meeting of the Society for Pediatric Research, San Francisco, CA, April 2006
8. Morris CR, Neumayr L, Wen A, Vichinsky E and the National Acute Chest Study Group.  Acute chest syndrome induces a reversible “asthma-like syndrome” in sickle cell disease. Annual meeting of the Society for Pediatric Research, San Francisco, CA, April 2006